| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $250,000 ) |
| | 2023 | 2023 | ANIVIVE LIFESCIENCES, INC. | 3250 AIRFLITE WAY # 400 | LONG BEACH | CA | 90807-5312 | LOS ANGELES | USA | R01FD007800 | Comparability protocol for 22.5 mg tablets (NADA # 141-526) | 000 | 1 | FDA | 12/7/2022 | $250,000 |
|
| Issue Date FY: 2021 ( Subtotal = $250,000 ) |
| | 2021 | 2021 | ANIVIVE LIFESCIENCES, INC. | 3250 AIRFLITE WAY # 400 | LONG BEACH | CA | 90807-5312 | LOS ANGELES | USA | R01FD006919 | A multi-center pivotal field study to confirm the effectiveness and safety of verdinexor for the treatment of lymphoma in dogs. | 000 | 2 | FDA | 5/25/2021 | $250,000 |
|
| Issue Date FY: 2020 ( Subtotal = $250,000 ) |
| | 2020 | 2020 | ANIVIVE LIFESCIENCES, INC. | 3250 AIRFLITE WAY # 400 | LONG BEACH | CA | 90807-5312 | LOS ANGELES | USA | R01FD006919 | A multi-center pivotal field study to confirm the effectiveness and safety of verdinexor for the treatment of lymphoma in dogs. | 000 | 1 | FDA | 5/5/2020 | $250,000 |
|
|
